Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IVAT Proposal Drafters Consider Alternatives, Faced With FDA Reservations

This article was originally published in The Gray Sheet

Executive Summary

Industry's in vitro diagnostic analytical test (IVAT) premarket proposal is unlikely to advance in its current form

You may also be interested in...



A Brewing Debate? ASR Reg Eyed As CMS Readies For Genetic Test Rule

Extending FDA's current analyte specific reagent rule to ASR kits would help address regulatory concerns about homebrew testing, diagnostic firms contend

A Brewing Debate? ASR Reg Eyed As CMS Readies For Genetic Test Rule

Extending FDA's current analyte specific reagent rule to ASR kits would help address regulatory concerns about homebrew testing, diagnostic firms contend

IVAT Proposal In Limbo As Industry Coalition Seeks Audience WIth FDA

Stakeholders are seeking clarification on agency concerns regarding industry's in vitro analytical test premarket proposal, following an Oct. 24 meeting between reps from OIVD and the IVAT industry coalition

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel